To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
360 Current news from the ressort finances
rss
Resolutions of the Annual General Meeting of Evotec
14-06-2013
Shareholders of Evotec AG approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting. The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2012 and ...
Merck’s credit rating raised by Standard & Poor’s to ‘A’
30-05-2013
Standard & Poor’s announced that it raised Merck's long- and short-term corporate credit and issue ratings to “A/A-1” from “A-/A-2”. The outlook is stable. Standard & Poor’s noted in its report: “The upgrade reflects our view that Merck’s credit metrics have continued to improve.” In March ...
Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013
16-05-2013
In the first six months of financial year 2012/2013 medical technology company Carl Zeiss Meditec increased its revenue by 2.6% compared with the same period of the previous year, to € 443 million. Earnings before interest and tax improved to € 64.1 million (previous year: € 61.1 million); ...
SYGNIS reports results for the first quarter of 2013
16-05-2013
SYGNIS Pharma AG announced its financial results according to IFRS for the first quarter of 2013, ending 31 March 2013. In the first quarter of 2013, revenues amounted to €0.1 million; operating expenses amounted to €1.3 million. Operating expenses include sales, general & administrative ...
ZEISS presents half-year financial figures
15-05-2013
During the first six months of fiscal year 2012/13 the business trend in the ZEISS Group was marked by the difficult conditions experienced in some markets. Nevertheless, the Group concluded the first half of the year (ended 31 March) with revenue totaling EUR 1.978 billion (first six months ...
Evogene reports first quarter 2013 financial results
14-05-2013
Evogene Ltd. (EVGN) announced its financial results for the first quarter ended March 31, 2013. Revenues for the first quarter of 2013 grew to $4.6 million, compared to $4.2 million for the same period in 2012. Evogene’s current revenues consist primarily of research and licensing revenues ...
Analytik Jena announces group figures for the first half of the financial year 2012/2013
10-05-2013
Analytik Jena AG (AJA) closed the first half of the financial year 2012/2013 with consolidated revenue of EUR 46.9 m and thus generated 2.0 % more than in the previous year. The manufacturer of analytical instrumentation technology, life science instruments and optoelectronics achieved an ...
Analytik Jena announces forecast for financial year 2012/2013
24-04-2013
Analytik Jena AG (AJA) expects sales for the current financial year 2012/2013 to exceed EUR 100.0 m for the first time in the Company's history. This was announced today by the manufacturer of analytical instrumentation, life science instruments and optoelectronics in the run-up to its Annual ...
New products create optimism for the future
Bayer: continuing growth momentum
01-03-2013
2012 was a very successful year for the Bayer Group. “We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items,” said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on ...
Evotec achieves milestone in drug discovery collaboration with Ono
15-01-2013
Evotec AG announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. This collaboration project was initiated in March 2008. Evotec ...
Netmeeting
